Clinical Trial Update: Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update evaluating maintenance therapy with tagraxofusp and azacitidine in CD123-positive acute myeloid leukemia and myelodysplastic syndr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• Elzonris (tagraxofusp)
• VIDAZA (AZACITIDINE)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Status: RECRUITING